Researchers reported a high-throughput strategy to engineer bispecific antibodies intended to strengthen macrophage-mediated killing of B-cell lymphoma cells. The approach, described in Nature Communications, centers on improving how antibodies coordinate immune-cell targeting and execution of malignant B cells by leveraging macrophage effector functions rather than relying only on tumor-intrinsic sensitivity. The work is positioned as a potential route to next-generation immunotherapies built around innate immune action.